Associations between vitamin D-binding protein isotypes, circulating 25(OH)D levels, and vitamin D metabolite uptake in colon cancer cells

Cancer Prevention Research

Volumn 7, Issue 4, 2014, Pages 426-434

  Hibler, Elizabeth A ^a   Jacobs, Elizabeth T ^a   Stone, Angelika Dampf ^b   Sardo, Christine L ^a   Galligan, Michael A ^b   Jurutka, Peter W ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; ALCOHOL; URSODEOXYCHOLIC ACID; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR; 25-HYDROXYVITAMIN D; CALCITRIOL RECEPTOR; DNA; ISOPROTEIN;

AGED; ARTICLE; CANCER CELL; COLON CANCER; COLORECTAL TUMOR; FEMALE; GENE INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPORTER GENE; SIGNAL TRANSDUCTION; VITAMIN BLOOD LEVEL; ADULT; ANALOGS AND DERIVATIVES; BLOOD; COLORECTAL NEOPLASMS; DOUBLE BLIND PROCEDURE; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DNA, NEOPLASM; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CALCITRIOL; TUMOR CELLS, CULTURED; URSODEOXYCHOLIC ACID; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 84898890463     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0269     Document Type: Article

References (50)

1. Davis CD. Vitamin D and cancer: current dilemmas and future research needs. Am J Clin Nutr 2008;88:565S-9S.
2. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011;128:1414-24.
3. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Ann Epidemiol 2009;19:468-83.
4. Giovannucci E. Vitamin D and Cancer Incidence in the Harvard Cohorts. Ann Epidemiol 2009;19:84-8.
5. IOM. Dietary Reference Intake for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.
6. Adams JS, Hewison M. Update in Vitamin D. J Clin Endocrinol Metab 2010;95:471-8.
7. Dixon KM, Mason RS. Vitamin D. Int J Biochem Cell Biol 2009;41:982-5.
8. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 2008;88:491S-9S.
9. Willnow TE, Nykjaer A. Cellular uptake of steroid carrier proteins-mechanisms and implications. Mol Cell Endocrinol 2010;316:93-102.
10. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clinica Chimica Acta 2006;372:33-42. (Pubitemid 44286753)
11. Gomme PT, Bertolini J. Therapeutic potential of vitamin D-binding protein. Trends Biotechnol 2004;22:340-5. (Pubitemid 38887542)
12. Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, et al. The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol Biomarkers Prev 2008;17:1339-43.
13. Christiansen M, Jorgensen CS, Laursen I, Hirschberg D, Hojrup P, Houen G. Protein chemical characterization of Gc globulin (vitamin D-binding protein) isoforms; Gc-1f, Gc-1s and Gc-2. Biochim Biophys Acta 2007;1774:481-92.
14. Arnaud J, Constans J. Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet 1993;92:183-8. (Pubitemid 23272286)
15. Fu L, Yun F, Oczak M, Wong BY, Vieth R, Cole DE. Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH)D] to vitamin D supplementation. Clin Biochem 2009;42:1174-7.
16. Haddad J. The Vitamin D binding protein and its clinical significance. In: Holick MF, editor. Vitamin D: Physiology, Molecular Biology, and Clinical Applications. Totowa, NJ: Humana Press, Inc.; 1999. p. 101-7.
17. Hibler EA, Hu C, Jurutka PW, Martinez ME, Jacobs ET. Polymorphic variation in the GC and CASR genes and associations with vitamin D metabolite concentration and metachronous colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2012;21:368-75.
18. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005;289:F8-28.
19. Harriss DJ, Atkinson G, Batterham A, George K, Cable NT, Reilly T, et al. Lifestyle factors and colorectal cancer risk (2): a systematic review and meta-analysis of associations with leisure-time physical activity. Colorectal Dis 2009;11:689-701.
20. Hartman TJ, Albert PS, Snyder K, Slattery ML, Caan B, Paskett E, et al. The association of calcium and vitamin D with risk of colorectal adenomas. J Nutr 2005;135:252-9. (Pubitemid 40194487)
21. Lee JE, Li H, Chan AT, Hollis BW, Lee IM, Stampfer MJ, et al. Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-analysis of prospective studies. Cancer Prev Res 2011;4:735-43.
22. Chun RF, Lauridsen AL, Suon L, Zella LA, Pike JW, Modlin RL, et al. Vitamin D-binding protein directs monocyte responses to 25-hydroxy- and 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab 2010;95:3368-76.
23. Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005;97:846-53. (Pubitemid 40909127)
24. Alberts DS, Martinez ME, Roe DJ, Guillen-Rodriguez JM, Marshall JR, van Leeuwen JB, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000;342:1156-62. (Pubitemid 30211046)
25. Martinez ME, Reid ME, Guillen-Rodriguez J, Marshall JR, Sampliner R, Aickin M, et al. Design and baseline characteristics of study participants in the Wheat Bran Fiber trial. Cancer Epidemiol Biomarkers Prev 1998;7:813-6. (Pubitemid 28420621)
26. Jacobs ET, Alberts DS, Benuzillo J, Hollis BW, Thompson PA, Martinez ME. Serum 25(OH)D levels, dietary intake of vitamin D, and colorectal adenoma recurrence. J Steroid Biochem Mol Biol 2007;103:752-6. (Pubitemid 46401330)
27. Egan JB, Thompson PA, Ashbeck EL, Conti DV, Duggan D, Hibler E, et al. Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence. Cancer Res 2010;70:1496-504.
28. Levine AJ, Figueiredo JC, Won L, Poynter JN, Conti D, Duggan DJ, et al. Genetic variability in the MTHFR gene and colorectal cancer risk in the colorectal cancer family registry. Cancer Epidemiol Biomarkers Prev 2009;19:89-100.
29. Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL. Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem 1993;39:529-33. (Pubitemid 23099026)
30. Hollis BW. Assay of circulating 1,25-dihydroxyvitamin D involving a novel single-cartridge extraction and purification procedure. Clin Chem 1986;32:2060-3. (Pubitemid 17029196)
31. Jacobs E, Martinez ME, Buckmeier J, Lance P, May M, Jurutka P. Circulating fibroblast growth factor-23 is associated with increased risk for metachronous colorectal adenoma. J Carcinog 2011;10:3.
32. Jacobs ET, Alberts DS, Foote JA, Green SB, Hollis BW, Yu Z, et al. Vitamin D insufficiency in southern Arizona. Am J Clin Nutr 2008;87:608-13. (Pubitemid 351364541)
33. Bartik L, Whitfield GK, Kaczmarska M, Lowmiller CL, Moffet EW, Furmick JK, et al. Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. J Nutr Biochem 2010;21:1153-61.
34. Jacobs ET, Van Pelt C, Forster RE, Zaidi W, Hibler EA, Galligan MA, et al. CYP24A1 and CYP27B1 Polymorphisms Modulate Vitamin D Metabolism in Colon Cancer Cells. Cancer Res 2013;73:2563-73.
35. Ahn J, Albanes D, Berndt SI, Peters U, Chatterjee N, Freedman ND, et al. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 2009;30:769-76.
36. Sinotte M, Diorio C, Berube S, Pollak M, Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 2009;89:634-40.
37. Lauridsen AL, Vestergaard P, Hermann AP, Brot C, Heickendorff L, Mosekilde L, et al. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int 2005;77:15-22. (Pubitemid 41504168)
38. Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr 2008;87:1087S-91S. (Pubitemid 351549268)
39. Nykjaer A, Fyfe JC, Kozyraki R, Leheste JR, Jacobsen C, Nielsen MS, et al. Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3). Proc Natl Acad Sci U S A 2001;98:13895-900. (Pubitemid 33115995)
40. Rowling MJ, Kemmis CM, Taffany DA, Welsh J. Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. J Nutr 2006;136:2754-9. (Pubitemid 44771769)
41. Adorini L, Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol 2007;103:689-93. (Pubitemid 46401347)
42. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001;154:369-87. (Pubitemid 34286147)
43. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, Sandler RS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999;340:101-7. (Pubitemid 29054844)
44. Wei MY, Garland CF, Gorham ED, Mohr SB, Giovannucci E. Vitamin D and prevention of colorectal adenoma: a meta-analysis. Cancer Epidemiol Biomark Prev 2008;17:2958-69.
45. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006;98:451-9.
46. Ng K, Wolpin BM, Meyerhardt JA, Wu K, Chan AT, Hollis BW, et al. Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer. Br J Cancer 2009;101:916-23.
47. Zheng XE, Lipka S, Li T, Shahzad G, Levine E, Vlacancich R, et al. The relationship of vitamin D status, smoking, and colorectal adenoma: A retrospective study in an ethnically diverse community. J Steroid Biochem Mol Biol 2013;136:280-3.
48. Aloia JF. African Americans, 25-hydroxyvitamin D, and osteoporosis: a paradox. Am J Clin Nutr 2008;88:545S-50S.
49. Atkins GJ, Anderson PH, Findlay DM, Welldon KJ, Vincent C, Zannettino AC, et al. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone 2007;40:1517-28. (Pubitemid 46756427)
50. Wang C, Hu YM, He JW, Gu JM, Zhang H, Hu WW, et al. Association between low density lipoprotein receptor-related protein 2 gene polymorphisms and bone mineral density variation in Chinese population. PloS ONE 2011;6:e28874.